Last updated on: 7/10/2017 | Author:

Ronald Paulus, MD, MBA Biography

President and CEO of Mission Health
Not Clearly Pro or Con to the question "Should Marijuana Be a Medical Option?"

“I have a mixed, science-based view of the pros and cons of marijuana… [I]t is in fact quite possible that broader legalization of marijuana could help more people with unmanageable pain find relief; it could even have a positive, mitigating effect against the opioid epidemic…

Typically, the age to legally consume marijuana is set at 21, but it would be naïve to assume that easier availability would not have a trickle-down impact and that the drug would find its way to those under legal age. And we know for certain that heavy recreational use of cannabinoids can adversely affect the brains of young people –pre-adolescents to those in their early 20s…

Marijuana should be treated in a science-based manner like all other drugs that have positive impact on patients and also serious side effects. Framing it as either a ‘boogeyman’ or a ‘perfectly safe panacea’ is nonsensical. Legalization is a complex political choice, particularly given conflicting interpretation among states and the federal government; but from a science standpoint it is very clear that more robust research should be pursued.”

“Mission Health’s President & CEO Clarifies Position on Medical Marijuana, Differs from July 1 Asheville Citizen-Times Report,”, July 2, 2017

Involvement and Affiliations:
  • President and CEO, Mission Health, Sep. 2010-present
  • Regional Policy Board Member, American Hospital Association, 2012-2015
  • Board Member, Asheville Chamber of Commerce, June 2011-June 2014
  • Executive Vice President, Clinical Operations, and Chief Innovation Officer, Geisinger Health System, May 2005-Aug. 2010
  • Chief Healthcare Officer, Quovadx, Inc., Sep. 2003-May 2005
  • President and CEO, CareScience, Inc., Mar. 1993-Sep. 2003
  • Vice President, Operations, Salick Health Care, Inc., June 1989-Mar. 1993
  • MD, University of Pennsylvania School of Medicine, 1988
  • MBA, Health Care Management, The Wharton School, 1988
  • BS, Economics, The Wharton School, 1984
  • None found
Quoted in:
  1. Should Marijuana Be Reclassified as a Schedule II or III Drug?